Organ preservation in rectal cancer: Have all questions been answered?

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages e13-e22

  Marijnen, Corrie A M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DEFECATION URGENCY; DISEASE FREE SURVIVAL; DRUG SAFETY; ENDOSCOPIC BIOPSY; ENDOSCOPIC SURGERY; FALSE POSITIVE RESULT; FECES INCONTINENCE; HIGH RISK PATIENT; HUMAN; LOCAL EXCISION; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE ESCALATION; RADIATION SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECTUM RESECTION; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CONSERVATIVE TREATMENT; MINIMAL RESIDUAL DISEASE; MINIMALLY INVASIVE SURGERY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; RECTAL NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; MINIMALLY INVASIVE SURGICAL PROCEDURES; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; ORGAN SPARING TREATMENTS; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84926102413     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70398-5     Document Type: Review

References (88)

1. Frykholm GJ, Glimelius B, Påhlman L Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993, 36:564-572.
2. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30:1926-1933.
3. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-820.
4. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011, 12:575-582. the Dutch Colorectal Cancer Group.
5. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
6. Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014, 15:184-190. the EORTC Radiation Oncology Group.
7. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
8. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012, 30:3827-3833.
9. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005, 23:8697-8705. the Swedish Rectal Cancer Trial Group.
10. Den Oudsten BL, Traa MJ, Thong MS, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer 2012, 48:3161-3170.
11. Pachler J, Wille-Jørgensen P Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 2012, 12. CD004323.
12. Morris EJ, Whitehouse LE, Farrell T, et al. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme. Br J Cancer 2012, 107:757-764.
13. Borschitz T, Heintz A, Junginger T The influence of histopathologic criteria on the long-term prognosis of locally excised pT1 rectal carcinomas: results of local excision (transanal endoscopic microsurgery) and immediate reoperation. Dis Colon Rectum 2006, 49:1492-1506.
14. Bach SP, Hill J, Monson JR, et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg 2009, 96:280-290. the Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration.
15. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004, 240:711-717.
16. Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014, 88:822-828.
17. Glynne-Jones R, Hughes R Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012, 99:897-909.
18. Bhangu A, Brown G, Nicholls RJ, Wong J, Darzi A, Tekkis P Survival outcome of local excision versus radical resection of colon or rectal carcinoma: a Surveillance, Epidemiology, and End Results (SEER) population-based study. Ann Surg 2013, 258:563-569.
19. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011, 29:4633-4640.
20. Lim L, Chao M, Shapiro J, et al. Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. Dis Colon Rectum 2007, 50:2032-2039.
21. Hughes R, Harrison M, Glynne-Jones R Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?. Acta Oncol 2010, 49:378-381.
22. Dalton RS, Velineni R, Osborne ME, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?. Colorectal Dis 2012, 14:567-571.
23. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010, 11:835-844.
24. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010, 53:1692-1698.
25. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?. Dis Colon Rectum 2008, 51:10-19.
26. Smith FM, Wiland H, Mace A, Pai RK, Kalady MF Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum 2014, 57:311-315.
27. Garcia-Aguilar J, Shi Q, Thomas CR, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012, 19:384-391.
28. Perez RO, Habr-Gama A, Pereira GV, et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?. Colorectal Dis 2012, 14:714-720.
29. Kuo LJ, Chiou JF, Tai CJ, et al. Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy?. Int J Colorectal Dis 2012, 27:613-621.
30. De Graaf EJ, Doornebosch PG, Tollenaar RA, et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur J Surg Oncol 2009, 35:1280-1285.
31. Steele GD, Herndon JE, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 1999, 6:433-441.
32. Mendenhall WM, Morris CG, Rout WR, et al. Local excision and postoperative radiation therapy for rectal adenocarcinoma. Int J Cancer 2001, 96(suppl):89-96.
33. Gerard JP, Chapet O, Ortholan C, Benezery K, Barbet N, Romestaing P French experience with contact X-ray endocavitary radiation for early rectal cancer. Clin Oncol (R Coll Radiol) 2007, 19:661-673.
34. Park IJ, You YN, Skibber JM, et al. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. Dis Colon Rectum 2013, 56:135-141.
35. Read TE, Andujar JE, Caushaj PF, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum 2004, 47:825-831.
36. Pucciarelli S, Capirci C, Emanuele U, et al. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol 2005, 12:111-116.
37. Bujko K, Richter P, Smith FM, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study. Radiother Oncol 2013, 106:198-205.
38. Gagliardi G, Newton TR, Bailey HR Local excision of rectal cancer followed by radical surgery because of poor prognostic features does not compromise the long term oncologic outcome. Colorectal Dis 2013, 15:e659-e664.
39. van Gijn W, Brehm V, de Graaf E, et al. Unexpected rectal cancer after TEM: outcome of completion surgery compared with primary TME. Eur J Surg Oncol 2013, 39:1225-1229.
40. Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012, 99:1211-1218.
41. Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum 2013, 56:1349-1356.
42. Swellengrebel HA, Marijnen CA, Verwaal VJ, et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 2011, 98:418-426.
43. Lezoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135 patients with small nonadvanced low rectal cancer (iT1-iT2, iN0): short- and long-term results. Surg Endosc 2011, 25:1222-1229.
44. Marks JH, Valsdottir EB, DeNittis A, et al. Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. Surg Endosc 2009, 23:1081-1087.
45. Coco C, Rizzo G, Mattana C, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc 2013, 27:2860-2867.
46. Doornebosch PG, Tollenaar RA, Gosselink MP, et al. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. Colorectal Dis 2007, 9:553-558.
47. Gornicki A, Richter P, Polkowski W, et al. Anorectal and sexual functions after preoperative radiotherapy and full-thickness local excision of rectal cancer. Eur J Surg Oncol 2014, 40:723-730.
48. You YN, Roses RE, Chang GJ, et al. Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum 2012, 55:1213-1219.
49. Roels S, Duthoy W, Haustermans K, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 2006, 65:1129-1142.
50. Leibold T, Shia J, Ruo L, et al. Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J Clin Oncol 2008, 26:2106-2111.
51. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999, 17:2396.
52. Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg 2003, 90:996-998. the Lyons Oncology Group.
53. Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008, 15:2661-2667.
54. Supiot S, Bennouna J, Rio E, et al. Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. Colorectal Dis 2006, 8:430-435.
55. Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 2012, 19:2833-2841.
56. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009, 250:582-589.
57. Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008, 248:243-251.
58. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004, 47:279-286.
59. Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013, 100:933-939. the Dutch Surgical Colorectal Audit.
60. Wang Y, Cummings B, Catton P, et al. Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol 2005, 77:126-132.
61. Radu C, Berglund A, Påhlman L, Glimelius B Short-course preoperative radiotherapy with delayed surgery in rectal cancer-a retrospective study. Radiother Oncol 2008, 87:343-349.
62. Hatfield P, Hingorani M, Radhakrishna G, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009, 92:210-214.
63. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 2012, 99:577-583.
64. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010, 97:580-587.
65. Latkauskas T, Pauzas H, Gineikiene I, et al. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis 2012, 14:294-298.
66. Ahmad NR, Marks G, Mohiuddin M High-dose preoperative radiation for cancer of the rectum: impact of radiation dose on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1993, 27:773-778.
67. Fortier GA, Constable WC, Meyers H, Wanebo HJ Preoperative radiation therapy for rectal cancer. An effective therapy in need of a clinical trial. Arch Surg 1986, 121:1380-1385.
68. Gerard JP, Romestaing P, Chapet O Radiotherapy alone in the curative treatment of rectal carcinoma. Lancet Oncol 2003, 4:158-166.
69. Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004, 22:2404-2409.
70. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 2012, 84:949-954.
71. Engels B, Platteaux N, Van den Begin R, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol 2014, 110:155-159.
72. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29:2773-2780.
73. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13:679-687. the German Rectal Cancer Study Group.
74. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014, 32:1927-1934.
75. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012, 30:4558-4565.
76. Schmoll HJ, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. J Clin Oncol 2014, 32(suppl). abstr 3501.
77. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011, 254:97-102. the Timing of Rectal Cancer Response to Chemoradiation Consortium.
78. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:241-248.
79. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010, 28:859-865.
80. van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013, 24:1762-1769.
81. Myerson RJ, Tan B, Hunt S, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 2014, 88:829-836.
82. Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, et al. Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol 2013, 107:171-177. the Polish Colorectal Study Group.
83. Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer 2013, 13:279.
84. Ciammella P, Ruggieri MP, Galeandro M, D'Abbiero N, Giunta A, Iotti C Short-course preoperative radiotherapy combined with chemotherapy in resectable locally advanced rectal cancer: local control and quality of life. Radiol Med (Torino) 2013, 118:1397-1411.
85. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014, 32:513-518.
86. Chemotherapy alone or chemotherapy plus radiation therapy in treating patients with locally advanced rectal cancer undergoing surgery NCCTG, (accessed Dec 7, 2014). http://clinicaltrials.gov/ct2/show/NCT01515787.
87. Lee JH, Kim JG, Oh ST, et al. Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02). Radiother Oncol 2014, 110:150-154.
88. Doi H, Beppu N, Odawara S, et al. Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer. J Radiat Res (Tokyo) 2013, 54:1118-1124.